<DOC>
	<DOCNO>NCT01214603</DOCNO>
	<brief_summary>Study JWYB multicenter , non-randomized , open-label , Phase 2 study intravenous LY2090314 participant acute leukemia .</brief_summary>
	<brief_title>A Study Participants With Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<criteria>Participants must confirm diagnosis one following : Acute myelogenous leukemia ( AML ) refractory relapse disease . If participant acute promyelocytic leukemia ( APL ) , must receive prior alltrans retinoic acid arsenic trioxide unless ineligible intolerant Untreated AML ( de novo arise myelodysplastic syndrome ) . In opinion investigator , participant candidate standard therapy clinical trial prefer treatment option Have give write informed consent prior studyspecific procedure Have adequate organ function include : Hepatic : Bilirubin le equal 1.5 time upper limit normal ( ULN ) . Alkaline phosphatase transaminase ( ALT AST ) less equal 5 time ULN Renal : Serum creatinine less equal ULN . No known active renal disease . In rare case , participant may enter treatment serum creatinine great ULN elevation serum creatinine may secondary dehydration Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous approved therapy acute leukemia , include chemotherapy least 14 day , recover acute effect therapy . Hydroxyurea use control peripheral blast count permit within first 2 cycle treatment study , must stop least 24 hour study drug administration Cycle 3 Are reliable willing available duration study willing follow study procedure Males female reproductive potential must agree use medically approve contraceptive precaution trial 3 month follow last dose study drug Females childbearing potential must negative urine serum pregnancy test less equal 7 day prior first dose study drug Have estimate life expectancy great equal 6 week Have receive treatment within 14 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication Participants Chronic Myelogenous Leukemia ( CML ) include blast crisis phase Participants known central nervous system ( CNS ) leukemia spinal fluid cytology image Have serious preexist medical condition ( leave discretion investigator ) Have one follow abnormality : QTc ( Fridericia correct ) interval &gt; 450 millisecond ( msec ) screen electrocardiogram ( ECG ) , previous history QTc prolongation another medication require discontinuation , congenital long QT syndrome , previous history ventricular tachycardia unexplained syncope , leave bundle branch block , chronic atrial fibrillation Have family history long QT syndrome sudden death due ventricular arrhythmia Concomitant medication may cause QTc prolongation induce Torsades de Pointes time study entry Have systolic blood pressure great equal 160 millimeter mercury ( mm Hg ) diastolic blood pressure great equal 100 mm Hg Have serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class II high participant history arrhythmia symptomatic require treatment Have uncorrected electrolyte disorder include potassium Have active malignancy ( exception basal squamous cell skin cancer ) time study entry Have receive autologous allogeneic stemcell transplant within 75 day initial dose study drug Have uncontrolled systemic infection Females pregnant lactate Presence clinical evidence viral disease cause human immunodeficiency virus , hepatitis B , hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Acute Myelogenous Leukemia , Acute Myeloid Leukemia , Acute</keyword>
	<keyword>Leukemia , Leukemia</keyword>
</DOC>